Assessing the net financial benefits of employing digital endpoints in clinical trials
Abstract In the last few decades, developers of new drugs, biologics, and devices have increasingly leveraged digital health technologies (DHTs) to assess clinical trial digital endpoints. To our knowledge, a comprehensive assessment of the financial net benefits of digital endpoints in clinical tri...
Saved in:
Main Authors: | Joseph A. DiMasi (Author), Abigail Dirks (Author), Zachary Smith (Author), Sarah Valentine (Author), Jennifer C. Goldsack (Author), Thomas Metcalfe (Author), Upinder Grewal (Author), Lada Leyens (Author), Ute Conradi (Author), Daniel Karlin (Author), Lesley Maloney (Author), Kenneth A. Getz (Author), Bert Hartog (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series
by: Michael S. Yule, et al.
Published: (2024) -
Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series
by: Marianne J. Hjermstad, et al.
Published: (2024) -
Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series
by: James McDonald, et al.
Published: (2023) -
Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series
by: Leo R. Brown, et al.
Published: (2024) -
Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series
by: Ola Magne Vagnildhaug, et al.
Published: (2024)